Literature DB >> 33170557

Phenotypic features in MECP2 duplication syndrome: Effects of age.

Sarika U Peters1, Cary Fu1, Eric D Marsh2, Tim A Benke3, Bernard Suter4, Steve A Skinner5, David N Lieberman6, Shannon Standridge7, Mary Jones8, Arthur Beisang9, Timothy Feyma9, Peter Heydeman10, Robin Ryther11, Daniel G Glaze4, Alan K Percy12, Jeffrey L Neul1.   

Abstract

BACKGROUND: MECP2 Duplication syndrome (MDS) is a rare X-linked genomic disorder that is caused by interstitial chromosomal duplications at Xq28 encompassing the MECP2 gene. Although phenotypic features in MDS have been described, there is a limited understanding of the range of severity of these features, and how they evolve with age.
METHODS: The cross-sectional results of N = 69 participants (ages 6 months-33 years) enrolled in a natural history study of MDS are presented. Clinical severity was assessed using a clinician-report measure as well as a parent-report measure. Data was also gathered related to the top 3 concerns of parents as selected from the most salient symptoms related to MDS. The Child Health Questionnaire was also utilized to obtain parental reports of each child's quality of life to establish disease burden.
RESULTS: The results of linear regression from the clinician-reported measure show that overall clinical severity scores, motor dysfunction, and functional skills are significantly worse with increasing age. Top concerns rated by parents included lack of effective communication, abnormal walking/balance issues, constipation, and seizures. Higher levels of clinical severity were also related to lower physical health quality of life scores as reported by parents.
CONCLUSIONS: The data suggest that increasing levels of clinical severity are noted with older age, and this is primarily attributable to motor dysfunction, and functional skills. The results provide an important foundation for creating an MDS-specific severity scale highlighting the most important domains to target for treatment trials and will help clinicians and researchers define clinically meaningful changes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  gene duplication; pediatrics; phenotype

Mesh:

Substances:

Year:  2020        PMID: 33170557      PMCID: PMC8000774          DOI: 10.1002/ajmg.a.61956

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  28 in total

1.  MECP2 Duplication Syndrome.

Authors:  H Van Esch
Journal:  Mol Syndromol       Date:  2011-07-05

2.  Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales.

Authors:  Katherine V Barnes; Francesca R Coughlin; Heather M O'Leary; Natalie Bruck; Grace A Bazin; Emily B Beinecke; Alexandra C Walco; Nicole G Cantwell; Walter E Kaufmann
Journal:  J Neurodev Disord       Date:  2015-09-15       Impact factor: 4.025

3.  Dendritic arborization and spine dynamics are abnormal in the mouse model of MECP2 duplication syndrome.

Authors:  Minghui Jiang; Ryan T Ash; Steven A Baker; Bernhard Suter; Andrew Ferguson; Jiyoung Park; Jessica Rudy; Sergey P Torsky; Hsiao-Tuan Chao; Huda Y Zoghbi; Stelios M Smirnakis
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

Review 4.  Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities.

Authors:  Wendy A Gold; Rahul Krishnarajy; Carolyn Ellaway; John Christodoulou
Journal:  ACS Chem Neurosci       Date:  2017-12-15       Impact factor: 4.418

Review 5.  The MECP2 duplication syndrome.

Authors:  Melissa B Ramocki; Y Jane Tavyev; Sarika U Peters
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

6.  Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28.

Authors:  Michael J Friez; Julie R Jones; Katie Clarkson; Herbert Lubs; Dianne Abuelo; Jo-Ann Blaymore Bier; Shashidhar Pai; Richard Simensen; Charles Williams; Philip F Giampietro; Charles E Schwartz; Roger E Stevenson
Journal:  Pediatrics       Date:  2006-11-06       Impact factor: 7.124

7.  Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.

Authors:  Jui-Hua Tsai; Ann O Scheimann; Shawn E McCandless; Theresa V Strong; John F P Bridges
Journal:  J Med Econ       Date:  2018-10-16       Impact factor: 2.448

8.  Further delineation of the MECP2 duplication syndrome phenotype in 59 French male patients, with a particular focus on morphological and neurological features.

Authors:  Marguerite Miguet; Laurence Faivre; Jeanne Amiel; Mathilde Nizon; Renaud Touraine; Fabienne Prieur; Laurent Pasquier; Mathilde Lefebvre; Julien Thevenon; Christèle Dubourg; Sophie Julia; Catherine Sarret; Ganaëlle Remerand; Christine Francannet; Fanny Laffargue; Odile Boespflug-Tanguy; Albert David; Bertrand Isidor; Jacqueline Vigneron; Bruno Leheup; Laetitia Lambert; Christophe Philippe; Mylène Béri-Dexheimer; Jean-Marie Cuisset; Joris Andrieux; Ghislaine Plessis; Annick Toutain; Laurent Guibaud; Valérie Cormier-Daire; Marlene Rio; Jean-Paul Bonnefont; Bernard Echenne; Hubert Journel; Lydie Burglen; Sandrine Chantot-Bastaraud; Thierry Bienvenu; Clarisse Baumann; Laurence Perrin; Séverine Drunat; Pierre-Simon Jouk; Klaus Dieterich; Françoise Devillard; Didier Lacombe; Nicole Philip; Sabine Sigaudy; Anne Moncla; Chantal Missirian; Catherine Badens; Nathalie Perreton; Christel Thauvin-Robinet; Réseau AChro-Puce; Jean-Michel Pedespan; Caroline Rooryck; Cyril Goizet; Catherine Vincent-Delorme; Bénédicte Duban-Bedu; Nadia Bahi-Buisson; Alexandra Afenjar; Kim Maincent; Delphine Héron; Jean-Luc Alessandri; Dominique Martin-Coignard; Gaëtan Lesca; Massimiliano Rossi; Martine Raynaud; Patrick Callier; Anne-Laure Mosca-Boidron; Nathalie Marle; Charles Coutton; Véronique Satre; Cédric Le Caignec; Valérie Malan; Serge Romana; Boris Keren; Anne-Claude Tabet; Valérie Kremer; Sophie Scheidecker; Adeline Vigouroux; Marilyn Lackmy-Port-Lis; Damien Sanlaville; Marianne Till; Maryline Carneiro; Brigitte Gilbert-Dussardier; Marjolaine Willems; Hilde Van Esch; Vincent Des Portes; Salima El Chehadeh
Journal:  J Med Genet       Date:  2018-04-04       Impact factor: 6.318

9.  Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.

Authors:  Clare Cutri-French; Dallas Armstrong; Joni Saby; Casey Gorman; Jane Lane; Cary Fu; Sarika U Peters; Alan Percy; Jeffrey L Neul; Eric D Marsh
Journal:  Ann Neurol       Date:  2020-06-29       Impact factor: 10.422

10.  Developmental delay in Rett syndrome: data from the natural history study.

Authors:  Jeffrey L Neul; Jane B Lane; Hye-Seung Lee; Suzanne Geerts; Judy O Barrish; Fran Annese; Lauren McNair Baggett; Katherine Barnes; Steven A Skinner; Kathleen J Motil; Daniel G Glaze; Walter E Kaufmann; Alan K Percy
Journal:  J Neurodev Disord       Date:  2014-07-22       Impact factor: 4.025

View more
  3 in total

1.  Medical Comorbidities in MECP2 Duplication Syndrome: Results from the International MECP2 Duplication Database.

Authors:  Daniel Ta; Jenny Downs; Gareth Baynam; Andrew Wilson; Peter Richmond; Helen Leonard
Journal:  Children (Basel)       Date:  2022-04-28

2.  MECP2 duplication syndrome: The electroclinical features of a case with long-term evolution.

Authors:  Ilaria Cani; Lorenzo Muccioli; Francesco Mignani; Laura Licchetta; Paolo Tinuper; Federica Provini; Francesca Bisulli
Journal:  Epilepsy Behav Rep       Date:  2022-04-19

3.  Exploring the characteristics and most bothersome symptoms in MECP2 duplication syndrome to pave the path toward developing parent-oriented outcome measures.

Authors:  Muharrem Ak; Bernhard Suter; Zekeriya Akturk; Holly Harris; Kristina Bowyer; Laurence Mignon; Sasidhar Pasupuleti; Daniel G Glaze; Davut Pehlivan
Journal:  Mol Genet Genomic Med       Date:  2022-06-15       Impact factor: 2.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.